Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.
Dr. Reddy's Laboratories Ltd. is gearing up to launch 26 products in GLP-1 (glucagon-like peptide-1) category in the next 10 years and the first one will be the generic of Semaglutide, a key product scheduled for launch by January 2026, the company's management said in a post-earnings press conference on Wednesday. GLP-1 category drugs are used to treat diabetics and obesity and the category has several products, for which the patents are set to expire 2026 onwards.
Share this Story:
